Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.05 USD
-0.04 (-0.23%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $17.06 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
EWTX 17.05 -0.04(-0.23%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EWTX
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Other News for EWTX
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insulet (PODD), Recursion Pharmaceuticals (RXRX) and Edgewise Therapeutics (EWTX)
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Edgewise Therapeutics (EWTX) Receives a Buy from Piper Sandler
Edgewise Therapeutics Unveils 2024 Equity Incentive Plan
Truist biotech analyst holds an analyst/industry conference call